Skip to content
Back to HRMY

Harmony Biosciences Holdings, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
13
Purchases
0
Sales
13
Purchase value
$0.00
Sale value
$5.95M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Kumar BudurCHIEF MEDICAL OFFICER
4
Filed Sep 18, 2026Period of report Sep 16, 20260002009762-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 18, 2026
Common StockF1F335,852$43.0545$1.54M13,115Direct
SaleSep 17, 2026
Common StockF1800$43.00$34.40K13,115Direct
SaleSep 16, 2026
Common StockF1F21,800$43.0146$77.43K13,115Direct
Filing footnotes · 5
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
  5. F5The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Open on SEC EDGAR
Kumar BudurCHIEF MEDICAL OFFICER
4
Filed Sep 9, 2026Period of report Sep 4, 20260002009762-26-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 8, 2026
Common StockF1F34,500$42.2475$190.11K14,115Direct
SaleSep 8, 2026
Common StockF1F41,000$42.7947$42.79K13,115Direct
SaleSep 8, 2026
Common StockF1F522,954$43.1014$989.35K13,115Direct
SaleSep 4, 2026
Common StockF1F25,500$41.9839$230.91K18,615Direct
Filing footnotes · 7
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $42.32. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.59 to $42.57. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.59 to $43.02. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F6The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date
  7. F7The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Open on SEC EDGAR
Sandip KapadiaCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Jan 28, 2026Period of report Jan 26, 20260001677141-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 26, 2026
Common StockF1F2F33,746$37.152$139.17K24,521Direct
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing.
Open on SEC EDGAR
Sandip KapadiaCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Jan 20, 2026Period of report Jan 15, 20260001677141-26-000001
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 15, 2026
Common StockF1F220,961$35.9159$752.83K0Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Jeffrey M. DaynoDirector · PRESIDENT, CEO
4Rule 10b5-1 plan disclosed
Filed Dec 17, 2025Period of report Dec 12, 20250001615993-25-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 12, 2025
Common StockF1F220,000$40.1073$802.15K0Direct
SaleDec 12, 2025
Common StockF1F25,933$40.1073$237.96K0Direct
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.28. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The stock option vests in five equal annual installments beginning on November 1, 2018.
Open on SEC EDGAR
Sandip KapadiaCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Dec 9, 2025Period of report Dec 5, 20250001677141-25-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 5, 2025
Common StockF1F220,000$39.5448$790.90K0Direct
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.63. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The stock option shall vest with respect to 50% of the underlying shares on March 23, 2023 and with respect to the remaining shares, in twenty-four equal monthly installments beginning on April 23, 2023.
Open on SEC EDGAR
Sandip KapadiaCHIEF FINANCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Nov 25, 2025Period of report Nov 21, 20250001677141-25-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 21, 2025
Common StockF13,427$35.00$119.95K0Direct
Filing footnotes · 1
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.